You have 9 free searches left this month | for more free features.

Condition

Bladder Carcinoma (1)

Healthy (1)

Nephritis, Lupus (1)

Non-small Cell Lung Cancer (1)

Overall Status

Unknown status (2)

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

phase 2/phase 3 (1)

Sponsor

Hadassah Medical Organization (1)

NKMAX Co., Ltd. (1)

Peking Union Medical College Hospital (1)

University Hospital, Bordeaux (1)

Collaborator

Intervention

gc (4)

avelumab (1)

cetuximab (1)

cyclophosphamide (1)

okt3 (1)

okt3, gc (1)

snk01 (super natural killer cells 01) (1)

tripterygium wilfordii hook f (1)

Study Documents

Intervention Type

drug (4)

biological (1)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (4)

gc

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Bladder Carcinoma Trial in France (Avelumab, GC)

Terminated

Bladder Carcinoma

Avelumab
GC

Besançon, France
+12 more

Apr 26, 2022

NSCLC Trial in Seoul (SNK01 (Super Natural Killer Cells 01), GC, Cetuximab)

Recruiting

Non-small Cell Lung Cancer

SNK01 (Super Natural Killer Cells 01)
+2 more

Seoul, Songpa-gu, Korea, Republic of

Asan Medical Center

Jul 15, 2021

Nephritis, Lupus Trial in Beijing (Tripterygium wilfordii Hook F, Cyclophosphamide, GC)

Unknown status

Nephritis, Lupus

Tripterygium wilfordii Hook F
+2 more

Beijing, Beijing, China

Deptment of Rheumatology, Peking Union Medical College Hospital

Jul 19, 2012

Healthy Trial in Boston, Jerusalem (OKT3, OKT3, GC, GC)

Unknown status

Healthy

OKT3
+2 more

Boston, Massachusetts
+1 more

Feb 3, 2009